Sanofi-Genzyme BioVentures (SGBV) is an important component of Sanofi’s broader global strategy to invigorate external innovation and research that will ultimately lead to new products. SGBV has leveraged the venture capital investment expertise and platform of its predecessor fund, Genzyme Ventures, with a recently-expanded mandate to invest across the more expansive footprint of Sanofi.
Originally established in 2001 as Genzyme Ventures, SGBV invests directly in private early-stage companies with promising new products based on breakthrough science.
Today, SGBV is a $100 million fund with a portfolio of direct equity investments in a variety of promising private life-science companies.
The mission of SGBV is to invest directly in private early-stage biotech companies with promising new products based on breakthrough science. As a strategic fund, investments are made to develop and forge relationships that could lead to future strategic collaborations and product opportunities. We seek investments that align with Sanofi’s current and future areas of business interest and will be championed by our research, development and division management teams.
In addition to financing, we provide our portfolio companies with guidance and advice by leveraging Sanofi’s established expertise in science, preclinical and clinical development, regulatory, manufacturing, commercialization, and more. In return, we expect an ongoing window into the company's progress and future products, through advisory committee membership, technical update meetings, board observer or director positions and a defined path to participation in potential partnering discussions.
All investment decisions are made by a small committee of senior Sanofi executives.
Our portfolio companies are varied in their focus but united in one important way: a commitment to innovative science and translational development that could change the future of medicine.
Bernard Davitian has extensive experience in the life sciences and biotech industry, marked by a number of closed transactions involving financings and M&A. His track record includes, among others, the successful IPO of Transgene on the NASDAQ and Euronext in 1998 ($100 million raised) and the sale of Fovea Pharmaceuticals to Sanofi in 2009 in a €370 million cash transaction.
Bernard joined Sanofi in 2010 as Vice President, Deputy of Global Head, Corporate Licenses and was promoted to Vice President, BD Licensing and Structured Investments in 2012, a role that includes the management of SGBV. Prior to his joining Sanofi, Bernard was EVP & CFO of Fovea Pharmaceuticals, CEO of Neurotech, and EVP & CFO of Transgene. Bernard began his career in the biotech sector by serving in various capacities at Institut Mérieux (now Sanofi Pasteur), including Corporate CFO.
In addition to his SGBV-related Boards of Directors responsibilities, which include Esperance Pharmaceuticals and Kahr Medical, Bernard also represents Sanofi on the Board of Directors of Warp Drive Bio.
Prior Sanofi role:
- Vice President, Deputy of Global Head, Corporate Licenses
- MSc in Management, Graduate School of Business of Lyon (EM Lyon, France)
- CPA (France)
- Wharton School of Business, Executive MBA (AMP program)
Partnering with Genzyme
Collaboration drives our external partnerships, where we seek complementary strengths that can help us bring groundbreaking new products to market.
Learn more about partnering